Real time Form 13D and 13G transaction reports:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Due to inconsistent filing format, it is highly recommended that you read the orignal filing form.
- Shares have beem adjusted for stock split.
"Insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise"
- Peter Lynch
What is insider trading>>
- Peter Lynch
What is insider trading>>
Reported DateTime | Transaction Date | Type | Company Symbol | Filed By Symbol | Shares Owned % Owned | Shares Vs. Prev Report | View |
2024-10-04 5:34 pm Purchase | 2024-09-24 | 13G | Pliant Therapeutics, Inc. PLRX | Paradigm Biocapital Advisors LP | 3,059,411 5.030% | 3,059,411![]() (New Position) | Filing History |
2024-05-02 4:34 pm Purchase | 2024-04-22 | 13G | Kura Oncology, Inc. KURA | Paradigm Biocapital Advisors LP | 3,861,318 5.100% | 3,861,318![]() (New Position) | Filing History |
2024-04-08 5:09 pm Purchase | 2024-03-27 | 13G | Y-mAbs Therapeutics, Inc. YMAB | Paradigm Biocapital Advisors LP | 2,198,312 5.020% | 2,198,312![]() (New Position) | Filing History |
2024-02-14 5:57 pm Purchase | 2023-12-31 | 13G | Arcellx, Inc. ACLX | Paradigm Biocapital Advisors LP | 3,658,624 7.000% | 1,235,924![]() (+51.01%) | Filing History |
2024-02-14 4:08 pm Unchanged | 2023-12-31 | 13G | COMPASS Pathways plc CMPS | Paradigm Biocapital Advisors LP | 3,425,988 5.400% | 0 (Unchanged) | Filing History |
2024-02-14 4:08 pm Sale | 2024-01-26 | 13G | Corbus Pharmaceuticals Holdings, Inc. CRBP | Paradigm Biocapital Advisors LP | 0 0.000% | -399,658![]() (Position Closed) | Filing History |
2024-02-14 4:08 pm Sale | 2023-12-31 | 13G | Vor Biopharma Inc. VOR | Paradigm Biocapital Advisors LP | 6,457,293 9.500% | -20,706![]() (-0.32%) | Filing History |
2024-02-14 4:08 pm Purchase | 2023-12-31 | 13G | Viridian Therapeutics, Inc. VRDN | Paradigm Biocapital Advisors LP | 5,304,313 9.990% | 2,993,615![]() (+129.55%) | Filing History |
2024-02-14 4:08 pm Purchase | 2023-12-31 | 13G | Olema Pharmaceuticals, Inc. OLMA | Paradigm Biocapital Advisors LP | 7,903,600 14.300% | 100,000![]() (+1.28%) | Filing History |
2024-02-14 4:08 pm Purchase | 2023-12-31 | 13G | Nuvalent, Inc. NUVL | Paradigm Biocapital Advisors LP | 3,858,008 6.700% | 478,928![]() (+14.17%) | Filing History |
2024-02-14 4:08 pm Purchase | 2023-12-31 | 13G | Disc Medicine, Inc. IRON | Paradigm Biocapital Advisors LP | 2,385,857 9.900% | 1,149,939![]() (+93.04%) | Filing History |
2024-02-14 4:08 pm Purchase | 2023-12-31 | 13G | Bicycle Therapeutics plc BCYC | Paradigm Biocapital Advisors LP | 3,707,001 9.800% | 2,096,336![]() (+130.15%) | Filing History |
2024-02-14 4:08 pm Purchase | 2023-12-31 | 13G | Autolus Therapeutics plc AUTL | Paradigm Biocapital Advisors LP | 12,611,335 7.200% | 2,512,751![]() (+24.88%) | Filing History |
2024-02-14 4:08 pm Purchase | 2023-12-31 | 13G | Ambrx Biopharma Inc. AMAM | Paradigm Biocapital Advisors LP | 4,502,689 7.100% | 4,502,689![]() (New Position) | Filing History |
2024-02-14 4:08 pm Purchase | 2023-12-31 | 13G | Alpine Immune Sciences, Inc. ALPN | Paradigm Biocapital Advisors LP | 3,176,743 5.500% | 859,109![]() (+37.07%) | Filing History |
2024-02-05 4:21 pm Purchase | 2024-01-26 | 13G | Corbus Pharmaceuticals Holdings, Inc. CRBP | Paradigm Biocapital Advisors LP | 399,658 9.000% | 399,658![]() (New Position) | Filing History |
2024-01-22 5:05 pm Purchase | 2024-01-12 | 13G | Tarsus Pharmaceuticals, Inc. TARS | Paradigm Biocapital Advisors LP | 1,927,506 5.800% | 1,927,506![]() (New Position) | Filing History |
2024-01-02 5:20 pm Purchase | 2023-12-20 | 13G | COMPASS Pathways plc CMPS | Paradigm Biocapital Advisors LP | 3,425,988 5.400% | 3,425,988![]() (New Position) | Filing History |
2023-10-30 5:12 pm Purchase | 2023-10-19 | 13G | Nuvalent, Inc. NUVL | Paradigm Biocapital Advisors LP | 3,379,080 5.900% | 3,379,080![]() (New Position) | Filing History |
2023-09-25 5:24 pm Purchase | 2023-09-14 | 13G | Ambrx Biopharma Inc. AMAM | Paradigm Biocapital Advisors LP | 25,172,784 5.700% | 25,172,784![]() (New Position) | Filing History |